Oooh. Probably should have posted this BEFORE the Benadryl drip
))))
Well,I can still blame the iPad spellchecker.
Im 90 minutes away from my first dose of yet another study drug, mk2206 whIch is an akt inhibitor. It is a small molecule dru, take in pill form, which targets a growth signaling pathway downstream from her2...- as well as some others if I recollect the slide at sabcs correctly.
It's somewhat back to the future for me - this is the trial iwas trying to get into last June, but couldn't because my platelets were too low post TDM1.
It is another phase 1 dose escalation study, but in this case they have already found the MTD and are just expanding participants in at that dose. Unlike the mm302 trial that didn't do much but maybe was just not a high enough dose in my case.
So perhaps there is a reason why this trial was a no-go for me last year..
Although the mk2206 is a targeted therapy, In dthis study it is combined with herceptin and taxol, so in a way that's kinda back to the future too as my initial therapy in 2004 was TCH.
Hoping this will be a killer combo!